Superluminal Medicines Receives $33 Million Investment

Superluminal Medicines Inc., a generative biology and chemistry company developing a differentiated production line, revolutionising the speed and accuracy of drug creation, has received investment. It announced the closing of a $33 million funding round. The investment was led by Insight Partners with significant participation from NVIDIA. It was also led by RA Capital Management. Gaingels also participated in the financing. The funding will be used to advance Superluminal's small molecule drug discovery programmes, initially focused on high-value G protein-coupled receptor (GPCR) targets.

Also See: Finnish Startup Paptic Receives €23 Million Investment

Superluminal Medicines

Superluminal Medicines is a productive biology and chemistry company developing a differentiated production pipeline, revolutionising the speed and accuracy of drug creation. The company's platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning and proprietary big data infrastructure. Its predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target precise structural change for therapeutic effect. The discovery engine is powered by industry-leading pharmacokinetic and toxicology in silico prediction capability. In anticipation of a lead programme candidate in the near term, the company's proprietary product pipeline validates its platform with initial programmes focused on high-value GPCR targets. Headquartered in Boston, the company is backed by a strong investor network including RA Capital, Insight Partners, NVIDIA and Gaingels.